title: Adjuvant chemotherapy and radiotherapy in triple-negative breast carcinoma: a prospective randomized controlled multi-center trial.
abstract: OBJECTIVE
  Triple-negative breast cancer (TNBC) presents a high risk breast cancer that lacks the benefit from hormone treatment, chemotherapy is the main strategy even though it exists in poor prognosis. Use of adjuvant radiation therapy, which significantly decreases breast cancer mortality, has not been well described among poor TNBC women. The aim of this study was to evaluate whether the combination of chemotherapy and radiotherapy could significantly increase survival outcomes in TNBC women after mastectomy.
  
  
  METHODS
  A prospective randomized controlled multi-center study was performed between February 2001 and February 2006 and comprised 681 women with triple-negative stage I-II breast cancer received mastectomy, of them, 315 cases received systemic chemotherapy alone, 366 patients received radiation after the course of chemotherapy. Recurrence-free survival (RFS) and overall survival (OS) were estimated. Simultaneously local and systemic toxicity were observed.
  
  
  RESULTS
  After a median follow-up of 86.5 months, five-year RFS rates were 88.3% and 74.6% for adjuvant chemotherapy plus radiation and adjuvant chemotherapy alone, respectively, with significant difference between the two groups (HR 0.77 [95% CI 0.72, 0.98]; P=0.02). Five-year OS significantly improved in adjuvant chemotherapy plus radiation group compared with chemotherapy alone (90.4% and 78.7%) (HR 0.79 [95% CI 0.74, 0.97]; P=0.03). No severe toxicity was reported.
  
  
  CONCLUSIONS
  Patients received standard adjuvant chemotherapy plus radiation therapy was more effective than chemotherapy alone in women with triple-negative early-stage breast cancer after mastectomy.
authors.affiliation: Department of Radiation Oncology, Fourth Military Medical University, Xi'an, China.
authors.forename: Jianhua
authors.initials: J
authors.lastname: Wang
authors.forename: Mei
authors.initials: M
authors.lastname: Shi
authors.forename: Rui
authors.initials: R
authors.lastname: Ling
authors.forename: Yuesheng
authors.initials: Y
authors.lastname: Xia
authors.forename: Shanquan
authors.initials: S
authors.lastname: Luo
authors.forename: Xuehai
authors.initials: X
authors.lastname: Fu
authors.forename: Feng
authors.initials: F
authors.lastname: Xiao
authors.forename: Jianping
authors.initials: J
authors.lastname: Li
authors.forename: Xiaoli
authors.initials: X
authors.lastname: Long
authors.forename: Jianguo
authors.initials: J
authors.lastname: Wang
authors.forename: Zengxia
authors.initials: Z
authors.lastname: Hou
authors.forename: Yunxia
authors.initials: Y
authors.lastname: Chen
authors.forename: Bin
authors.initials: B
authors.lastname: Zhou
authors.forename: Man
authors.initials: M
authors.lastname: Xu
mesh_terms: D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000737:chemistry / Q000401:mortality / Q000628:therapy*; D059248:Chemoradiotherapy; D017024:Chemotherapy, Adjuvant; D005260:Female; D019398:Genes, BRCA1; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D011446:Prospective Studies; D018714:Radiotherapy, Adjuvant; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis; D011960:Receptors, Estrogen / Q000032:analysis; D011980:Receptors, Progesterone / Q000032:analysis
chemical_list: D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; C508053:ERBB2 protein, human